Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3922056 | 1.00 | PDE4A (0.32) | PDE4ALMNAL3MBTL1TDP1USP2 | |
| SCHEMBL315273 | 1.00 | PDE4A (0.32) | PDE4ALMNAL3MBTL1TDP1USP2 | |
| Hydrochloric Acid SCHEMBL5866744 | 0.98 | PDE4A (0.31) | PDE4ALMNAL3MBTL1 | |
| SCHEMBL4981902 | 0.77 | — | — | |
| SCHEMBL4990227 | 0.76 | USP2 (0.32) | USP2SLCO1B1 | |
| SCHEMBL4268666 | 0.74 | — | — | |
| SCHEMBL27539360 | 0.73 | LMNA (0.36) | PDE4ALMNAL3MBTL1TDP1USP2 | |
| SCHEMBL4861016 | 0.73 | LMNA (0.37) | PDE4ALMNAL3MBTL1TDP1USP2 | |
| SCHEMBL4744788 | 0.70 | USP2 (0.38) | PDE4ALMNAL3MBTL1TDP1USP2 | |
| SCHEMBL3624773 | 0.70 | USP2 (0.38) | PDE4ALMNAL3MBTL1TDP1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9277697-B2 | Compositions and methods for anti-transpiration in plants | INNOVATION HAMMER, LLC (US) | 2016-03-08 | — | — | US | claimed |
| US-20150250171-A1 | Compositions And Methods For Anti-Transpiration In Plants | INNOVATION HAMMER LLC (US) | 2015-09-10 | — | — | US | claimed |
| EP-2804613-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF HEPATIC DISEASES AND DISORDERS | McKenna, Elizabeth (US) | 2014-11-26 | — | — | EP | claimed |
| WO-2013109635-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF HEPATIC DISEASES AND DISORDERS | MCKENNA ELIZABETH (US) | 2013-07-25 | — | — | WO | claimed |
| US-20260097055-A1 | COGNITION | CULLIS HILL SYDNEY DAVID (AU) | 2026-04-09 | — | — | US | disclosed |
| US-12521409-B2 | Cognition | CULLIS HILL SYDNEY DAVID (AU) | 2026-01-13 | — | — | US | disclosed |
| US-20250312396-A1 | Control of Cellular Redox Levels | MCKENNA ELIZABETH (US) | 2025-10-09 | — | — | US | disclosed |
| CN-119630404-A | Improved cognitive ability | S·D·卡利斯-希尔 | 2025-03-14 | — | — | CN | disclosed |
| US-20250032521-A1 | COGNITION | CULLIS HILL SYDNEY DAVID (AU) | 2025-01-30 | — | — | US | disclosed |
| EP-3373943-A1 | CONTROL OF CELLULAR REDOX LEVELS | Mckenna, Elizabeth (US) | 2018-09-19 | — | — | EP | disclosed |
| WO-2017083470-A1 | CONTROL OF CELLULAR REDOX LEVELS | MCKENNA ELIZABETH (US) | 2017-05-18 | — | — | WO | disclosed |
| EP-3102588-A1 | A KIT FOR PREPARING A RADIOPHARMACEUTICAL | The South African Nuclear Energy Corporation Limited (ZA) | 2016-12-14 | — | — | EP | disclosed |
| US-5672490-A | PROMOTING THE SPLITTING DNA BY MIXING WITH A SAPPHYRIN-EDTA CONJUGATE COMPOUND | THE UNIVERSITY OF TEXAS BOARD OF REGENTS (US) | 1997-09-30 | — | — | US | disclosed |
| US-5543514-A | Water-soluble sapphyrins | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1996-08-06 | — | — | US | disclosed |
| US-5530123-A | ANTIVIRAL AND CHEMOTHERAPEUTICAL AGENT FOR CANCER | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1996-06-25 | — | — | US | disclosed |
| US-5457195-A | Sapphyrin derivatives and conjugates | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1995-10-10 | — | — | US | disclosed |
| WO-1994009003-A1 | SAPPHYRIN DERIVATIVES, CONJUGATES AND POLYMERS THEREOF AND EXPANDED PORPHYRIN CHROMATOGRAPHIC SUPPORTS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1994-04-28 | — | — | WO | disclosed |
| US-5126329-A | Diagnosis of kidney disorders | NITTO BOSEKI CO., LTD. (JP) | 1992-06-30 | — | — | US | disclosed |
| EP-0061180-A1 | Method for the preparation of N-(N'(2-chloroethyl)-N'-nitroso)-carbamoyl-amino-acid glucose amides and tetra-acetyl glycose amides | Stiftung Deutsches Krebsforschungszentrum (DE) | 1982-09-29 | — | — | EP | disclosed |
| US-4216208-A | N-Acyl derivatives of glucosamines having antitumor chemotherapeutic activity | PROTER S.P.A. (IT) | 1980-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250032521-A1 | COGNITION | CSGALNACT1, GLA, OGT | PDE4A 2571/4885LMNA 4384/4885L3MBTL1 4735/4885 |
| US-20260097055-A1 | COGNITION | FUT5, GLA, CSGALNACT1 | PDE4A 548/4885LMNA 4192/4885L3MBTL1 3781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.